Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-8080 + dalpiciclib in ER+ HER2- metastatic breast cancer
NCT06167694Phase 2Recruiting
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Jun 2026
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-8080 in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 2 years, Maximum Tolerated Dose at 2 years and 3 more. Started Dec 2023; status: recruiting.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06167694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06167694.